203 related articles for article (PubMed ID: 31611628)
1. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.
Alanazi B; Munje CR; Rastogi N; Williamson AJK; Taylor S; Hole PS; Hodges M; Doyle M; Baker S; Gilkes AF; Knapper S; Pierce A; Whetton AD; Darley RL; Tonks A
Leukemia; 2020 Feb; 34(2):427-440. PubMed ID: 31611628
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
3. The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression.
Yao CY; Lin CC; Wang YH; Hsu CL; Kao CJ; Hou HA; Chou WC; Tien HF
J Formos Med Assoc; 2023 Jul; 122(7):636-647. PubMed ID: 36428148
[TBL] [Abstract][Full Text] [Related]
4. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.
de Jonge HJ; Woolthuis CM; Vos AZ; Mulder A; van den Berg E; Kluin PM; van der Weide K; de Bont ES; Huls G; Vellenga E; Schuringa JJ
Leukemia; 2011 Dec; 25(12):1825-33. PubMed ID: 21760593
[TBL] [Abstract][Full Text] [Related]
6. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR
PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100
[TBL] [Abstract][Full Text] [Related]
9. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
Capala ME; Vellenga E; Schuringa JJ
PLoS One; 2014; 9(10):e111568. PubMed ID: 25360637
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis.
Dong X; Fang Z; Yu M; Zhang L; Xiao R; Li X; Pan G; Liu J
Cell Physiol Biochem; 2018; 51(2):886-896. PubMed ID: 30466095
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.
Nakamura S; Nagata Y; Tan L; Takemura T; Shibata K; Fujie M; Fujisawa S; Tanaka Y; Toda M; Makita R; Tsunekawa K; Yamada M; Yamaoka M; Yamashita J; Ohnishi K; Yamashita M
PLoS One; 2011; 6(11):e28011. PubMed ID: 22132193
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells.
Xia L; Liu JY; Yang MY; Zhang XH; Jiang Y; Yin QQ; Luo CH; Liu HC; Kang ZJ; Zhang CT; Gao BB; Zhou AW; Cai HY; Waller EK; Yan JS; Lu Y
Cancer Res; 2024 Feb; 84(3):479-492. PubMed ID: 38095536
[TBL] [Abstract][Full Text] [Related]
13. JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
Nakamura S; Tan L; Nagata Y; Takemura T; Asahina A; Yokota D; Yagyu T; Shibata K; Fujisawa S; Ohnishi K
Mol Carcinog; 2013 Jan; 52(1):57-69. PubMed ID: 22086844
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance profile analysis of S100 family members in human acute myeloid leukemia.
Yang XY; Jin J; Huang J; Li P; Xue JW; Wu XJ; He ZX
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7324-7334. PubMed ID: 32706071
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.
Strassberger V; Gutbrodt KL; Krall N; Roesli C; Takizawa H; Manz MG; Fugmann T; Neri D
J Proteomics; 2014 Mar; 99():138-51. PubMed ID: 24487095
[TBL] [Abstract][Full Text] [Related]
16. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
17. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
18. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
19. CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
Juncà J; Garcia O; Garcia-Caro M; Vila J; Zamora L; Cabezón M; Alonso E; de la Banda E; Rodríguez-Hernández I; Ribera JM; Millá F
Ann Hematol; 2016 Dec; 95(12):1949-1954. PubMed ID: 27595757
[TBL] [Abstract][Full Text] [Related]
20. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
